18
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Coronary artery disease in Africa and the Middle East

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Countries in Africa and the Middle East bear a heavy burden from cardiovascular disease. The prevalence of coronary heart disease is promoted in turn by a high prevalence of cardiovascular risk factors, particularly smoking, hypertension, dyslipidemia, diabetes, and sedentary lifestyles. Patients in Africa and the Middle East present with myocardial infarction at a younger age, on average, compared with patients elsewhere. The projected future burden of mortality from coronary heart disease in Africa and the Middle East is set to outstrip that observed in other geographical regions. Recent detailed nationally representative epidemiological data are lacking for many countries, and high proportions of transient expatriate workers in countries such as Saudi Arabia and the United Arab Emirates complicate the construction of such datasets. However, the development of national registries in some countries is beginning to reveal the nature of coronary heart disease. Improving lifestyles (reducing calorie intake and increasing physical activity) in patients in the region will be essential, although cultural and environmental barriers will render this difficult. Appropriate prescribing of pharmacologic treatments is essential in the prevention and management of cardiovascular disease. In particular, recent controversies relating to the therapeutic profile of beta-blockers may have reduced their use. The current evidence base suggests that beta-blockers are as effective as other therapies in preventing cardiovascular disease and that concerns relating to their use in hypertension and cardiovascular disease have been overstated.

          Author and article information

          Journal
          Ther Clin Risk Manag
          Ther Clin Risk Manag
          Therapeutics and Clinical Risk Management
          Therapeutics and Clinical Risk Management
          Dove Medical Press
          1176-6336
          1178-203X
          2012
          2012
          16 February 2012
          : 8
          : 65-72
          Affiliations
          [1 ]Heart and Vascular Institute, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates
          [2 ]American University of Beirut Medical Center, Beirut, Lebanon
          [3 ]General and Cardiovascular Clinic of Tunis, Tunisia
          [4 ]Cairo University, Cairo, Egypt
          [5 ]King Khalid University Hospital and The Kingdom Hospital, Saudi Arabia
          [6 ]Ain Shams University School of Medicine, Cairo, Egypt
          [7 ]University of Milan, Bicocca, Milan, Italy
          Author notes
          Correspondence: Wael Almahmeed, Heart and Vascular Institute, Sheikh Khalifa Medical City, PO Box 51900, Abu Dhabi, United Arab Emirates, Tel +971 2610 3540, Fax +971 2610 4983, Email walmahmeed@ 123456skmc.ae
          Article
          tcrm-8-065
          10.2147/TCRM.S26414
          3284217
          22368447
          7007a731-a126-4522-aba1-9b472b08921f
          © 2012 Almahmeed et al, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          History
          Categories
          Review

          Medicine
          coronary heart disease,heart failure,cardiovascular disease,cardiovascular risk factors,beta-blockers

          Comments

          Comment on this article